Octylethylmethylamin | 65446-51-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Octylethylmethylamin
• 英文别名: ethyl-methyl-octyl-amine；Aethyl-methyl-octyl-amin；N-methyl-N-ethyl-n-octylamine；N-Ethyl-N-methyloctan-1-amine
• CAS: 65446-51-7
• 化学式: C₁₁H₂₅N
• 分子量: 171.326
• InChiKey: VBESUKCLGKGCEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  乙醇 、 2,4,6-tris-(7-methylamino-heptyl)-[1,3,5]trithiane, trihydrochloride 在 水 、 镍 作用下， 生成 Octylethylmethylamin
  参考文献：
  名称：

  Unsaturated Amines. XV. The Mercuric Acetate Oxidation of Medium Rings Containing Tertiary Nitrogen¹

  摘要：

  DOI：

  10.1021/ja01530a027

文献信息

• [EN] COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS<br/>[FR] COMPOSÉS, COMPOSITIONS, PROCÉDÉS POUR LE TRAITEMENT DE MALADIES ET PROCÉDÉS POUR LA PRÉPARATION DE COMPOSÉS
  申请人：UNIV LOUISVILLE RES FOUND INC

  公开号：WO2017019537A1

  公开（公告）日：2017-02-02

  Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

  该发明的一些实施例包括创新化合物（例如，式（I）的化合物）。其他实施例包括包括该创新化合物的组合物（例如，药物组合物）。该发明的另一些实施例包括使用创新化合物的组合物（例如，药物组合物）来治疗，例如使用创新化合物治疗某些疾病。一些实施例包括使用创新化合物的方法（例如，在组合物或药物组合物中）进行给药和治疗（例如，癌症等疾病）。进一步的实施例包括制备创新化合物的方法。此外，本文还讨论了该发明的其他实施例。
• NOVEL DISSYMMETRIC N,N-DIALKYLAMIDES, THE SYNTHESIS THEREOF AND USES OF SAME
  申请人：COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

  公开号：US20180222849A1

  公开（公告）日：2018-08-09

  Novel dissymmetric N,N-dialkylamides which meet the following formula (I): where R represents a linear or branched alkyl group at C 8 to C 15 . A method for synthesizing these N,N-dialkylamides, and to the uses of same as extractants, alone or in admixture, in order to extract uranium and/or plutonium from an aqueous acid solution, or to totally or separate uranium from plutonium from an aqueous acid solution and, in particular, an aqueous solution resulting from dissolving spent nuclear fuel in nitric acid. Further, a method for processing an aqueous solution resulting from the dissolution of a spent nuclear fuel in nitric acid, allowing the uranium and plutonium contained in the solution to be extracted, separated and decontaminated in a single cycle, without requiring any plutonium reduction operation, and in which one of the aforementioned N,N-dialkylamides or a mixture of same is used as extractant. Applications for the method include the processing of spent nuclear fuels, in particular comprising uranium (e.g. UOX) or uranium and plutonium (e.g. MOX).

  新颖的不对称N,N-二烷基酰胺，符合以下公式(I)：其中R代表C8到C15的直链或支链烷基基团。一种合成这些N,N-二烷基酰胺的方法，以及将其作为萃取剂单独使用或与其他物质混合以从水酸性溶液中萃取铀和/或钚，或者从水酸性溶液中完全或分离铀和钚，特别是从用硝酸溶解废核燃料后得到的水酸性溶液。此外，提供一种处理用硝酸溶解废核燃料后得到的水溶液的方法，允许在单个循环中提取、分离和脱污该溶液中含有的铀和钚，无需进行任何钚还原操作，并且其中使用上述N,N-二烷基酰胺或其混合物之一作为萃取剂。该方法的应用包括处理废核燃料，特别是包含铀（如UOX）或铀和钚（如MOX）的废核燃料。
• [EN] HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY<br/>[FR] AMIDES HETEROCYCLIQUES A ACTIVITE ANTAGONISTE DE L'ALPHA-4 INTEGRINE
  申请人：URIACH & CIA SA J

  公开号：WO2003084984A1

  公开（公告）日：2003-10-16

  The present invention relates to new compounds of Formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as integrin α4 antagonists.

  本发明涉及公式（I）的新化合物及其盐，溶剂合物和前药，其中各取代基的含义如描述中所披露。这些化合物可用作整合素α4拮抗剂。
• PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST
  申请人：TANIMOTO Koichi

  公开号：US20120202992A1

  公开（公告）日：2012-08-09

  Pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of formula [I]: wherein R 1 and R 2 are the same or different and each is an optionally substituted aryl group, etc., R 0 is hydrogen, an alkyl group, etc., E is —C(═O)— or —SO 2 —, R is a group of formula [i], [ii] or [iii], etc: Ring A is a C 3-8 cycloalkyl group optionally fused to a benzene ring or a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom, etc., R 3 is an alkyl group optionally substituted by an alkylthio group, R 4 is hydrogen atom, an alkyl group, etc., one of R A and R B is an alkyl group, etc., and the other is hydrogen, an alkyl group, etc., or a pharmaceutically acceptable salt thereof.

  一种具有CB1受体拮抗活性的吡唑并[1,5-a]嘧啶化合物，其化学式为[I]：其中R1和R2相同或不同，且每个都是可选取代的芳基基团等，R0为氢、烷基基团等，E为—C(═O)—或—SO2—，R为式[i]、[ii]或[iii]等的基团：环A为C3-8环烷基团，可选地融合到苯环或苯环上，Q为单键或亚甲基基团，环B为4-至7-成员的脂肪族杂环基团，所述环基团通过其环碳原子与相邻的氮原子结合，X为硫原子等，R3为可选取代的烷基基团，R4为氢原子、烷基基团等，RA和RB中的一个为烷基基团等，另一个为氢、烷基基团等，或其药学上可接受的盐。
• Anti-Viral Compounds
  申请人：DeGoey David A

  公开号：US20120220562A1

  公开（公告）日：2012-08-30

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  本发明描述了能够抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这样的化合物的过程、包含这样的化合物的组合物以及使用这样的化合物治疗HCV感染的方法。